Autopsy report · NCT04652570

Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

“Sponsor change”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 3 years 3 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Tenet Medicines

Sponsor type

Industry

Conditions

Membranous Nephropathy

Interventions

VB119

Participants

6

Sites

4

Countries

United States

Trials that died the same way

• Interest of Learning Self-hypnosis for Patients Awaiting Lung Transplantation
  “Change of sponsor” (97% match in meaning)
• VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure
  “Change in Sponsor” (96% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (88% match in meaning)
• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
  “Change in Sponsor strategy” (88% match in meaning)
• Effects of Dietary Supplements on Nail and Hair Health
  “Strategic change by sponsor” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.